Catabasis Pharmaceuticals, a biopharmaceutical company, completed the acquisition of Quellis Biosciences, a privately-held emerging biopharmaceutical company focused on discovering best-in-class new molecules to treat serious rare diseases. Financial terms were not disclosed. “Catabasis has worked diligently with external advisors to explore and evaluate a range of strategic options, and the Board and management team believe that this transaction represents an opportunity to create substantial value for Catabasis’ stockholders. Our mission has always been to bring life-changing therapies to patients and families affected by rare diseases. We look forward to progressing QLS-215, a differentiated and potential best-in-class new therapy for patients affected by HAE," Kenneth Bate, Catabasis Chair of the Board of Directors.